Completed PHASE3 INTERVENTIONAL NCT00259077

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy of Omeprazole 20mg and 10mg od for the Four-week Treatment of Non-erosive Reflux Disease (NERD) With That of Placebo od and to Investigate Safety

Sponsor: AstraZeneca

Conditions Non-erosive Reflux Disease

Interventions Omeprazole

Updated 7 times since 2017 Last updated: Jan 21, 2011 Started: Oct 31, 2003 Primary completion: Jul 31, 2004 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-erosive Reflux Disease and is currently completed. AstraZeneca leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Tanabe Pharma Corporation

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asa, Japan , Beppu, Japan , Chiyoda City, Japan , Fujieda, Japan , Fukuoka, Japan , Kanagawa, Japan , Kawagucki, Japan , Kita-ku, Japan , Kitakyushu, Japan , Kyoda, Japan and 16 more locations